作者: Arnab Das , Subhasis Barik , Anamika Bose , Soumyabrata Roy , Jaydip Biswas
DOI: 10.1016/J.IMLET.2014.08.004
关键词:
摘要: Abstract We have generated a polyclonal antibody against novel immunomodulator, neem leaf glycoprotein (NLGP) that can react to specific 47 kDa subunit of NLGP. Generated anti-NLGP (primarily IgG2a) was tested for its anti-tumor activity in murine carcinoma (EC, CT-26), sarcoma (S180) and melanoma (B16Mel) tumor models. Surprisingly, growth restriction only observed CT-26 models, without any alteration other systems. Comparative examination antigenicity between four different models revealed high expression CEA-like protein on the surface tumors. Subsequent cross-reactivity with purified or cell bound CEA prominent recognition by antibody, as detected ELISA, Western Blotting immunohistochemistry. This seems be responsible function expressing confirmed ADCC reaction + systems where dependency is equivalent anti-CEA antibody. Obtained result enormous therapeutic potential tumors may explained view epitope spreading concept, however, further investigation crucial.